Channel Therapeutics Corporation filings document material-event disclosures connected to the company's completed corporate combination and transition to Pelthos Therapeutics. The 8-K record covers material agreements, shareholder voting matters, capital-structure disclosure and governance matters, while the company's public-company context included NaV1.7-targeted, non-opioid pain therapeutic programs before the transition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Schedule 13G
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
How many Channel Therapeutics Corporation (CHRO) SEC filings are available on StockTitan?
StockTitan tracks 20 SEC filings for Channel Therapeutics Corporation (CHRO). Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for Channel Therapeutics Corporation (CHRO)?
The most recent SEC filing for Channel Therapeutics Corporation (CHRO) was filed on July 10, 2025.